Taxus Cardium Pharmaceuticals Group Inc., formerly Cardium Therapeutics, Inc., is a development-stage regenerative medicine biotechnology company. The Company is focused on the acquisition and strategic development of product opportunities or businesses having the potential to address unmet medical needs. The Company’s products include Generx and Excellagen. Generx, Cardium’s lead Phase III clinical study product candidate, is a transformative disease-modifying angiogenic gene therapy growth factor therapeutic that is being developed for the treatment of Cardiac Microvascular Insufficiency (CMI). Excellagen is Aseptic Pharmaceutically-Formulated Fibrillar Collagen developed based on technology through its acquisition of the Tissue Repair Company .The Company’s wholly owned subsidiaries include Tissue Repair Company, To Go Brands, Inc. and LifeAgain Insurance Solutions, Inc., an advanced medical data analytics business.